SLA and intrahepatic cholangiocarcinoma: Regarding SLA class II, co‐cultured shCIITA‐expressing cells with anti‐SLA class II‐specific antibodies showed a significant (P < .05) decrease in cytotoxicity levels compared to the SLA class II‐expressing ICC‐derived cells, 3098 ± 274 to 3915 ± 196 RLU, respectively (Figure 6B).